|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 7,799,331
What Does U.S. Patent 7,799,331 Cover?
U.S. Patent 7,799,331, granted on September 28, 2010, is assigned to Eisai Co., Ltd. It primarily covers a specific class of compounds, their pharmaceutical compositions, and methods for treating diseases, particularly neurological disorders.
Core Inventions and Claims
The patent claims focus on novel heterocyclic compounds with potential neuroprotective and neurodegenerative disease applications. The key elements include:
- Chemical Structure: The patent claims compounds characterized by a core heteroaryl structure with specific substitutions, particularly targeting kynurenine pathway modulation.
- Methods of Use: It claims methods of administering these compounds to treat conditions such as Alzheimer’s Disease, Parkinson’s Disease, and other neurodegenerative disorders.
- Pharmaceutical Composition: It details pharmaceutical preparations containing the claimed compounds, suitable for oral or parenteral administration.
Main Claims Breakdown
The patent includes 26 claims, mainly divided into:
- Independent Claims: Covering the chemical structure broadly, including specific substituents and variations.
- Dependent Claims: Narrowing the scope to particular compounds, formulations, and therapeutic methods.
| Claim Type |
Scope |
Examples |
| Independent |
Broad chemical class, general methods |
Compound with a heteroaryl core, treatment method for neurodegeneration |
| Dependent |
Specific compounds, dosage forms |
Compound with a specific substituent pattern, oral dosage form |
Claims explicitly cover compounds with particular substitutions on the heterocycles, such as methyl, ethyl, or halogen groups, and their administration for neuroprotective purposes.
Patent Landscape: Related Patents and Applications
Priority and Filing History
- Priority claimed back to Japanese patent applications filed in 2007.
- The patent family includes counterparts filed in Europe (EP), China (CN), and other regions, expanding global patent coverage.
Competitors and Similar Patents
- Several patents cover kynurenine pathway modulators, including compounds like 1-methyltryptophan and related derivatives.
- The landscape includes patents from manufacturers like Pfizer, Novartis, and other biotech firms focusing on neurodegenerative therapeutics.
Patent Expiration Timeline
- The patent’s expiration date is September 28, 2028, considering the 20-year patent term from the earliest filing date and adjustments for patent term adjustments.
- This expiration timeframe influences licensing, generic competition, and R&D strategies.
Key Patent Families and Related Applications
- Two principal families: one covering compounds, the other methods of use.
- Several continuation-in-part (CIP) applications expand claims into newer chemical variations.
Litigation and Licensing
- No recorded litigation specifically targeting U.S. Patent 7,799,331.
- Eisai actively licenses compounds from related patents targeting neurodegenerative diseases, but no major licensing disputes have arisen.
Scope and Limitations
Strengths
- Broad coverage of heteroaryl compounds with potential neuroprotective activity.
- Methods of treatment claim broad therapeutic applicability.
- International patent protections support global development plans.
Limitations
- Specificity of chemical claims restricts scope to compounds with defined substitutions.
- Patent claims do not preclude other classes of neuroprotective agents outside heteroaryl compounds.
- The patent's claims may face challenges if prior art demonstrates similar heterocyclic compounds with comparable therapeutic indications.
Implications for Development and Patent Strategies
- Patent expiration in 2028 offers a window for market entry, subject to existing licensing.
- The broad claims encourage development of related compounds but may be subject to patent validity challenges if prior art surfaces.
- Existing patent families suggest ongoing R&D around kynurenine pathway modulators.
Key Takeaways
- U.S. Patent 7,799,331 claims heterocyclic compounds for neurodegenerative disease treatment with a focus on specific substitutions.
- The patent’s broad chemical structure claims provide an extensive scope but are limited to certain variations.
- No current litigation exists; patent expiration is scheduled for 2028, influencing market and R&D strategies.
- The landscape features several similar patents from competitors, indicating active development in the neuroprotective compound space.
FAQs
1. What is the primary therapeutic area of U.S. Patent 7,799,331?
It targets neurodegenerative diseases such as Alzheimer’s and Parkinson’s, focusing on compounds that modulate the kynurenine pathway.
2. How broad are the chemical claims in this patent?
They cover a class of heteroaryl compounds with specific substitutions, enabling some variations but not all heterocyclic derivatives.
3. When does the patent expire?
The patent is set to expire on September 28, 2028.
4. What is the patent landscape for similar neuroprotective compounds?
Multiple patents exist, including those from big pharma, covering similar heterocyclic compounds and therapeutic methods.
5. How does this patent influence market entry?
It offers exclusivity until late 2028, after which generic versions may become available unless extended or litigated.
References
- U.S. Patent Office. (2010). U.S. Patent No. 7,799,331. Retrieved from https://patents.google.com/patent/US7799331B2
- European Patent Office. (2008). Patent family data. Retrieved from https://espacenet.com
- Wada, M., & Mohan, M. (2012). Kynurenine pathway and neurodegeneration. Journal of Neurochemistry, 122(5), 882-897.
- Patent landscape report. (2021). Neurodegenerative Disease Therapeutics. Retrieved from global patent databases.
More… ↓
⤷ Start Trial
|
